Introduction
============

The immune mechanism of the digestive system is very complex and consists of many synergistic interacting elements. The basis of this mechanism is glandular cells and inflammatory cells. Under normal conditions, inflammatory cells located in the glandular ducts are responsible for the balance in the immune system of the large intestine. Intestinal bacteria stimulate GALT-associated lymphoid tissue. The system consists of lymphocytes located in intestinal lymph nodes (Peyer\'s tufts), endothelial cells, and in the lamina propria ([@b1-etm-0-0-8146]).

Cancer cells stimulate hypoxia and local inflammatory mediators that activate numerous inflammatory cells, including a diverse population of lymphoid cells ([@b2-etm-0-0-8146]). Tumor Associated Antigens (TAA) are recognized and presented by the so-called antigen presenting cells (APCs) which MHC class II molecules on their surface. They include tumor-infiltrating lymphocytes (TILs) with phenotypes B and Th ([@b3-etm-0-0-8146]). In addition, tumor antigens can be bound by CD8^+^ T lymphocytes with MHC class I molecules ([@b4-etm-0-0-8146]). The heterogeneous density of tumor infiltrating immune cells was observed according to tumor location ([@b5-etm-0-0-8146]). Kwak *et al* ([@b5-etm-0-0-8146]) showed that CD3^+^ positive lymphocytes was the highest in invasive margin compare to those in the tumor center and distant metastasis. Moreover, authors confirmed a low density of CD8^+^ TILs in center of tumor in advanced colorectal cancer.

The tumor cells exhibit high histological and clinical heterogeneity and thus a high variability within the TAA. Decay or change in TAA is conditioned by the selection of clones that consist in submitting tumor cells to the action of an immune response. As a result of elimination, the cells with the highest survival and proliferation are selected. Next, the selected clones of altered antigenicity proliferate in an uncontrolled manner and condition further invasion of tumors to nearby tissues and distant organs ([@b6-etm-0-0-8146]). In colorectal cancer, metastatic spread of cancer was located mainly in the liver and lungs. Firstly, disseminating CRC cells come into portal circulation, then they situated in the liver parenchyma due to vessel fenestration. On the other hand, CRC cells can get into general circulation and lead to development of pulmonary metastases ([@b7-etm-0-0-8146]). Free antigens or fragments of their cell membranes inhibit co-stimulatory molecules on APC cells and block cytotoxic T lymphocyte activity by CLTA-4 ([@b8-etm-0-0-8146]). In addition, tumor cells may have numerous Fas (FasL) ligands on their surface that bind to its receptor on the surface of cytotoxic T lymphocytes. This leads to the death of these inflammatory cells and the elimination of an important element of the immune response ([@b9-etm-0-0-8146]). Therefore, immunotheraphies that aim to stimulate immune response have been successfully used in many malignant tumors such prostate cancer and malignant melanoma ([@b7-etm-0-0-8146]).

Therefore, it seems reasonable to assess the activity of the immune system in tissue material, in the form of TILs located in the invasive primary tumor front as well as those surrounding tumor cell deposits and in distal metastases to the liver in patients with colorectal cancer correlated with anatomoclinical parameters.

Materials and methods
=====================

The study was performed in conformity with the Declaration of Helsinki for Human Experimentation and the protocol was approved by the Bioethics Committee of the Medical University of Bialystok (no. R-I-002/352/2016). Written informed consent was obtained from all participants.

### Patients

The study group consisted of 163 patients diagnosed with colorectal carcinoma (female-56, male-88) and operated in the Department of Oncological Surgery, in Comprehensive Cancer Center of Bialystok, in years 2014--2016. Patients were divided into 3 groups: i) 123 cases of primary tumor colorectal cancer without distant metastasis, ii) 25 cases with deposits of colorectal cancer cells and iii) 15 cases of colorectal cancer liver metastasis. During routine diagnostics all patients underwent basic diagnostic laboratory tests, ECG, spirometry, arterial blood gasometric test as well X-ray and computerized tomography of the chest. The clinical efficiency was performed with a 5-point scale of Zubroda (WHO) ([@b10-etm-0-0-8146]). The clinical staging of CRC was evaluated according to TNM classification ([@b11-etm-0-0-8146]).

Patients diagnosed with neoplasms in rectum received preoperative therapy (N=60): Chemotherapy (N=9), radiotherapy (N=39) or radio-chemotherapy (N=12). They were administered a dose of 25 Gy in fractions of 5 Gy during one week in the pelvic area. Preoperatively, patients with tumors localized in a different site received neither inflammatory nor immunosuppressive therapy. Postoperatively, 64 cases received additional therapy: Chemotherapy (N=57), radiotherapy (N=3) or radio-chemotherapy (N=5). The type of pre/postoperative therapy was chosen on the basis of current recommendation for colorectal cancer treatment. The response to preoperative therapy was estimated according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria ([@b12-etm-0-0-8146]).

### Histopathological examination

Sections, 4 µm-thick, were cut from paraffin blocks and stained with hematoxylin and eosin (H&E) (no. cat. 468802128; POCH S.A.). The routine histopathological assessment of the sections referred to type of tumor growth, tumor size, histological type and percentage of the mucinous component, grade of malignancy, pTNM and Duke stages. We also analyzed venous, lymphatic and perineural invasions, characteristic features of lymph node invasion such as number of resected and invaded lymph nodes, presence of micro- and macrometastases, invasion of the pouch lymph node; presence of distant metastases and their size in millimeters. We also assessed the presence of deposits, their number and size in millimeters ([@b13-etm-0-0-8146]). Tumor deposits (TDs) are defined as focal aggregates of adenocarcinoma located in the pericolic or perirectal fat disassociated with the primary tumor ([@b14-etm-0-0-8146]). The inflammation infiltrate in both invasive front of the tumor and the center of the main mass was classified according the Klintrup-Makinen criteria ([@b15-etm-0-0-8146]). A detailed demographic characteristic of patients is shown in [Table I](#tI-etm-0-0-8146){ref-type="table"}.

### Analysis of Tumor-Infiltrating Lymphocytes

Tumor-Infiltrating Lymphocytes were assessed in tissue material stained with hematoxylin-eosin and by light microscopy (Leica DM6 B; KAWA.SKA) and evaluated by two independent pathologists blinded to the clinical information. The analyses of TILs were performed in i) the invasive front of primary tumor mass, ii) the areas surrounding deposits of cancer cells and iii) the invasive front of colorectal cancer liver metastasis. TILs were determined as a percentage of mononuclear inflammatory cells over total intratumoral stromal area and counted in 5 HPF (total magnification, ×200--400) in the invasive front or areas surrounding the deposits, except for tumor areas with crush artifacts, necrosis or regressive hyalinization ([@b16-etm-0-0-8146],[@b17-etm-0-0-8146]). We defined a lymphocyte as a small, rounded cell a large, dark-staining nucleus with little eosinophilic cytoplasm in diameter no more than 7 µm. There is the smallest nucleated cell which can be found in colorectal cancer tissue. For statistical analysis, three levels of infiltration in the stroma TILs were determined: 1 weak (0--10% of stromal TILs), 2-moderate (20--40% of stromal TILs) and 3-strong (50--90% of stromal TILs). Also, in order to conduct statistical analysis, we divided study group into: Group 1-(1 level of stromal TILs) and group 2-(2 and 3 levels of stromal TILs).

### Statistical analysis

Statistical analysis was conducted using the STATISTICA 10.0 program (Statsoft). χ^2^ test was used to compare the groups. Correlations between the parameters were calculated by the Spearman\'s correlation coefficient and χ^2^ tests. A P-value of \<0.05 was considered statistically significant.

Results
=======

### Tumor-Infiltrating Lymphocytes in primary tumor, around the deposits and in the invasive front of distant metastases to liver

TILs in the invasive front of primary tumor were weak in 72 cases, moderate in 30 cases and strong in 21 cases. Infiltration of TILs around the deposits of cancer cells was weak in 18 cases, moderate in 4 cases and strong in 3 cases. Patients with distant metastases to liver showed weak infiltration of TILs in 11 cases, moderate in 3 cases and strong in 1 case. The differences between all groups were statistically significant (P=0.003). The rults are shown in [Table II](#tII-etm-0-0-8146){ref-type="table"} and [Fig. 1](#f1-etm-0-0-8146){ref-type="fig"}.

### Correlations between TILs in the invasive front of primary tumor mass and anatomoclinical features

TILs in the invasive front of primary tumor mass were negatively correlated with venous, lymphatic and perineutral invasions (R=−0.321; P=0.009; R=−0.434, P=0.004; R-0.197, P=0.013), lymph node metastases, their number and invasion of pouch (R=−0.197, P=0.019; R=−0.358, P=0.004; R=−0.419, P=0.030).

### Correlation between TILs localized in areas around the deposits of cancer cells and in the invasive front of distant metastases to liver and anatomoclinical variables

TILs distributed around the deposits of cancer cells were associated with postoperative treatment (R=0.452; P=0.017) and stronger inflammatory cell infiltrate in the invasive front of tumor (R=0.439, P=0.040). TILs localized in the invasive front of liver metastases were positively correlated with preoperative treatment (R=0.559, P=0.030), pT stage (R=0.554, P=0.003) and inflammatory cell infiltrate in the invasive front of primary tumor (R=0.664, P=0.017). Moreover, TILs of liver metastases were negatively associated with lymph node metastases (R=−0.686, P=0.004) and presence of tumor deposits (R=−0.543, P=0.036) ([Tables III](#tIII-etm-0-0-8146){ref-type="table"} and [IV](#tIV-etm-0-0-8146){ref-type="table"}).

Discussion
==========

Lymphocytic infiltration is a major immunological defense against tumor cells in solid tumors and is a potential predictor of colorectal cancer ([@b18-etm-0-0-8146]--[@b20-etm-0-0-8146]). In our studies, we found a weak infiltration in 72 cases, moderate in 30 cases and strong in 21 cases. TILs may be stimulated by APC-lymphocytes, while the degree and direction of activation and selectivity of stromal TILs are dependent on the type of antigen on the tumor cell ([@b21-etm-0-0-8146]). TILs located in the invasive front are one of the first elements of host defense against invasive tumor cells that further stimulate or inhibit cellular response ([@b22-etm-0-0-8146]). In brief, there are correlations in which we observed invasions of tumor cells into blood vessels and lymph vessels, as well as perineutral space with a decrease in the amount of TILs. In addition, in patients with a low incidence of TILs in the invasive primary tumor front, we found metastases to the local lymph nodes and tumor invasion beyond the nodule to the surrounding tissues. The results of our study are consistent with the observations of Perez *et al* ([@b18-etm-0-0-8146]), Huh *et al* ([@b23-etm-0-0-8146]) and Pagès *et al* ([@b24-etm-0-0-8146],[@b25-etm-0-0-8146]). Also, Mlecnik *et al* ([@b26-etm-0-0-8146]) confirmed that the decrease in intratumoral immune T-cell densities correlated with the growth of the primary tumor and the metastatic spread of colorectal cancer cells. In our studies, we reported a significantly higher TILs infiltration in the primary tumor compared to their presence in the deposits and metastatic carcinoma of the intestinal carcinoma. The failure of TILs in subsequent stages of tumor invasion can be determined by several factors. It has been reported that TILs in colorectal cancer can undergo apoptosis ([@b19-etm-0-0-8146]). The phenotype of the lymphocytes which commonly contains Treg lymphocytes exerts a significant influence on the organization of TILs and its effectiveness ([@b27-etm-0-0-8146]). The status of microsatellite instability is not trivial. It has been shown that TILs of MSI-H colorectal cancers may be more immunoactive and cytotoxic than in MSS tumors ([@b28-etm-0-0-8146],[@b29-etm-0-0-8146]).

Cancer cells of primary tumors acquire an invasive phenotype and show features of metastasis ([@b30-etm-0-0-8146]). In the first place, the involvement of blood vessels and lymph nodes, regional lymph nodes and tumor cells crossing the border of the nodule are demonstrated. In some cases, patients with colorectal cancer show deposits of cancer cells (TDs) that are defined and classified as a feature N1C in the 7th edition of the AJCC/TNM staging system ([@b31-etm-0-0-8146]). There are tumor cells in the pericolorectal or adjacent mesocolic fats far away from the leading edge of the tumor. There should be no exclusion of residual lymph node tissue. Moreover, tumor deposits should be within the lymph drainage area of the primary carcinoma ([@b31-etm-0-0-8146]). It has been shown that the presence of colorectal cancer deposits may be an unfavorable predictor ([@b31-etm-0-0-8146]). To our knowledge, this was the first study to investigate the TILs surrounded by tumor deposits. We have mainly reported weak TILs in most cases. The infiltrate of TILs around cancer deposits positively correlated with postoperative treatment in the form of chemo or radiotherapy. Previous studies confirmed that the presence of deposits in patients with rectal cancer who underwent preoperative chemoradiotherapy was associated with a trend of higher local recurrence rate and significantly decreased survival ([@b32-etm-0-0-8146],[@b33-etm-0-0-8146]). The analysis of patients with rectal cancer who underwent preoperative radiotherapy treatment showed the relevance of TDs with several aggressive tumor features, including more intensive regional lymph nodes metastasis and more perineural invasion ([@b34-etm-0-0-8146]). Perhaps the preoperative treatment modifies the immune response around the deposits, probably into a poor TIL response, which results in the fact that they are an exponent of disease progression. There is also a possibility that it is the selected clones of tumor cells that build deposits escaping from the control of local inflammatory response and directly inhibit its organization, which is also expressed by the presence of a few cells. Therefore, perhaps the increase in the number of TILs around the deposit improves the effect of postoperative treatment. A limitation of our analysis in this case is the fact that the group of patients is not great and the study included neither a detailed breakdown of the deposits of patients with preoperative therapy used nor assessment of its effectiveness. In the future, we will expand our TILs analysis based on these criteria.

With the progression of cancer disease, tumor cells of the subsequent tissue structures, including the distal organs, can be observed. In our studies, we have shown a weak infiltrate of TILs in the invasive front of liver metastatic sites in approximately 73% of cases. In turn, Kwak *et al* ([@b5-etm-0-0-8146]) and Lee *et al* ([@b35-etm-0-0-8146]) have observed that higher densities of CD3^+^, CD8^+^ and CD45RO (+) TILs in distant metastases of colorectal cancer were significantly correlated with better prognosis. In contrast to the above studies, Schweiger *et al* ([@b36-etm-0-0-8146]) demonstrated that patients with pulmonary metastases from colorectal cancer have a high density of FOXP3 + TILs at invasive front and low density of CD8+ cells in TILs may have worse prognosis. In our studies, we have found correlations between TILs in the invasive frontal metastases of liver cancer and the use of preoperative treatment. Halama *et al* ([@b37-etm-0-0-8146]), showed that TIL densities at the invasive margin of liver metastases allowed the prediction of response to chemotherapy with a high sensitivity and specificity. Also Morris *et al* ([@b38-etm-0-0-8146]) TILs in patients treated with 5-fluorouracil-based chemotherapy were associated with significantly improved survival. There are indications that the presence of TILs in distant metastases may be conditioned and modified by both pre- and postoperative treatment.

In conclusion, the results of our study confirmed that the histopathological evaluation of TILs infiltration in both the primary tumor of colon cancer and its metastases in the form of deposits and cancer focus of liver may help to determine the extent of immune defense activation and provide a potential pathological outcome.
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###### 

Distribution of TILs. TIL distribution was observed (A) in the invasive front of primary tumor (strong cell infiltrate), (B) those surrounding deposits of cancer cells (weak cell infiltrate) and (C) in the invasive front of distant metastatic cells in the liver (weak cell infiltrate). Evaluation of TILs was performed using hematoxylin and eosin-stained sections. Magnification, ×200 in (A and C) and ×200 in (B) TILs, tumor-infiltrating lymphocytes.
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###### 

Demographic details of the study groups.

  Variables                         Primary tumor (N=123) (%)   Deposits of cancer cells (N=25) (%)   Liver metastases (N=15) (%)
  --------------------------------- --------------------------- ------------------------------------- -----------------------------
  Age (years)                                                                                         
    \<60                            29 (23.7)                   6 (24)                                1 (6.6)
    \>60                            94 (76.3)                   19 (76)                               14 (93.4)
  Sex                                                                                                 
    Female                          48 (39.0)                   10 (40)                               5 (33.3)
    Male                            75 (61.0)                   15 (60)                               10 (66.7)
  Localization                                                                                        
    Right-side                      13 (10.5)                   3 (12)                                2 (13.3)
    Transverse                      5 (4.0)                     1 (4)                                 1 (6.6)
    Left-side                       4 (3.2)                     1 (4)                                 2 (13.3)
    Sigmoid                         21 (17.3)                   5 (20)                                1 (6.6)
    Rectum                          80 (65.0)                   15 (60)                               9 (60.2)
  Tumor growth                                                                                        
    Expanding                       103 (83.7)                  20 (80)                               13 (98.7)
    Infiltrate                      20 (16.3)                   5 (20)                                2 (1.3)
  Tumor size                                                                                          
    \<2.5 cm                        20 (16.3)                   3 (12)                                2 (1.3)
    2.5--5.0 cm                     81 (65.8)                   20 (80)                               13 (98.7)
    \>5.0 cm                        22 (17.9)                   2 (8)                                 0 (0)
  TNM stage                                                                                           
    1                               17 (13.8)                   0 (0)                                 0 (0)
    2                               43 (34.9)                   0 (0)                                 0 (0)
    3                               58 (47.1)                   21 (84)                               0 (0)
    4                               2 (4.2)                     4 (16)                                15 (100)
  Lymph node metastasis                                                                               
    Absent                          65 (52.8)                   1 (4)                                 6 (39.8)
    Present                         58 (47.2)                   24 (96)                               9 (60.2)
  Distant metastasis                                                                                  
    Absent                          123 (100)                   21 (84)                               0 (0)
    Present                         0 (0)                       4 (16)                                15 (100)
  No. of metastases                                                                                   
    Single                          0 (0)                       3 (75)                                8 (53.4)
    Multiple                        0 (0)                       1 (25)                                7 (46.6)
  Distant metastasis size (mm)                                                                        
    \<5                             0 (0)                       1 (33.3)                              7 (46.6)
    \>5                             0 (0)                       2 (66.7)                              8 (53.4)
  Tumour deposits                                                                                     
    Absent                          123 (100)                   0 (0)                                 11 (63.7)
    Present                         0 (0)                       25 (100)                              4 (36.3)
  Preoperative treatment                                                                              
    Yes                             40 (32.6)                   7 (28)                                3 (2)
    No                              83 (67.4)                   18 (72)                               12 (80)
  Type of preoperative treatment                                                                      
    CHT                             5 (14)                      2 (28.5)                              0 (0)
    RHT                             29 (70)                     1 (14.2)                              3 (100)
    RHT+CHT                         6 (16)                      4 (57.3)                              0 (0)
  Preoperative treatment response                                                                     
    SD                              13 (26)                     3 (60)                                2 (66.7)
    PR                              17 (24)                     2 (40)                                1 (33.3)
  Postoperative treatment                                                                             
    Yes                             46 (37.3)                   5 (20)                                8 (53.4)
    No                              77 (62.7)                   20 (80)                               7 (46.6)
  Type of postoperative treatment                                                                     
    CHT                             40 (86.9)                   5 (100)                               6 (75)
    RHT                             2 (4.5)                     0 (0)                                 1 (12.5)
    RHT+CHT                         4 (8.6)                     0 (0)                                 1 (12.5)
  Disease-free survival                                                                               
    \<6 months                      38 (30.8)                   9 (36)                                6 (40)
    6--12 months                    27 (22.9)                   5 (20)                                3 (20)
    \>12 months                     57 (46.3)                   11 (44)                               6 (40)

RHT, radiotherapy; CHT, chemotherapy; SD, stable disease; PR, progression of disease.

###### 

Distribution of TILs.

  TIL location                                    N     Weak levels of TILs   Moderate levels of TILs   Strong levels of TILs   P-value
  ----------------------------------------------- ----- --------------------- ------------------------- ----------------------- ---------
  Invasive front of primary tumor                 123   72                    30                        21                      0.003
  Deposits of cancer cells                        25    18                    4                         3                       
  Invasive front of distant metastasis to liver   15    11                    3                         1                       

χ^2^ test. TILs, tumor-infiltrating lymphocytes.

###### 

Correlation between TILs in invasive primary tumor front, tumor cell deposits, and distant metastasis to liver and anatomoclinicaal parameters in patients with colorectal cancer.

                            TILs associated with invasive front of primary tumor (N=123)   TILs associated with deposits of cancer cells (N=25)   TILs associated with invasive front of distant metastastic cells in liver (N=15)                                                         
  ------------------------- -------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------- ---------- ---------- ------- ------------ ---------- -------
  Age                                                                                                                                                                                                                                                                                      
    \<60                    20 (16.2)                                                      9 (7.3)                                                NS                                                                                 3 (12.0)   3 (12.0)   NS      1 (6.6)      0 (0)      NS
    \>60                    42 (38.2)                                                      42 (38.2)                                                                                                                                 15 (60)    4 (16)             10 (66.6)    4 (26.6)   
  Sex                                                                                                                                                                                                                                                                                      
    Female                  24 (19.5)                                                      24 (19.5)                                              NS                                                                                 8 (40)     2 (8)              2 (13.3)     3 (20.0)   NS
    Male                    48 (39.1)                                                      27 (21.9)                                                                                                                                 10 (60)    5 (22)     NS      9 (60.1)     1(6.66)    
  Localization                                                                                                                                                                                                                                                                             
    Right-side              10 (8.3)                                                       3 (2.4)                                                NS                                                                                 1 (6.6)    2 (8)      NS      1 (6.66)     0 (0)      
    Transverse              3 (2.4)                                                        2 (1.6)                                                                                                                                   1 (6.6)    0 (0)              6 (40.0)     2 (13.3)   
    Left-side               4 (3.2)                                                        0 (0)                                                                                                                                     1 (6.6)    0 (0)              1 (6.66)     1 (6.66)   
    Sigmoid                 10 (8.3)                                                       11 (8.9)                                                                                                                                  14 (56)    4 (16)             1 (6.66)     1 (6.66)   
    Rectum                  44 (35.7)                                                      36 (29.2)                                                                                                                                 5 (20)     1 (6.6)            2 (13.3)     0 (0)      
  Tumor growth                                                                                                                                                                                                                                                                             
    Expanding               60 (49)                                                        44 (35.7)                                              NS                                                                                 15 (80)    5 (22)     NS      10 (66.6)    3 (20.0)   NS
    Infiltrate              12 (9.7)                                                       7 (5.6)                                                                                                                                   3 (12.0)   2 (8)              1 (6.66)     1 (6.66)   
  Tumor size                                                                                                                                                                                                                                                                               
    \<2.5 cm                18 (14.6)                                                      6 (4.8)                                                NS                                                                                 2 (8)      1 (6.6)    NS      1 (13.3)     1 (6.66)   NS
    2.5--5.0 cm             41 (33.6)                                                      34 (27.6)                                                                                                                                 14 (80)    6 (21.4)           10 (86.7)    3 (20.0)   
    \>5.0 cm                13 (10.5)                                                      11 (8.9)                                                                                                                                  2 (8)      0 (0)                                      
  TNM stage                                                                                                                                                                                                                                                                                
    1                       23 (18.6)                                                      20 (16.2)                                              NS                                                                                 0 (0)      0 (0)      NS      0 (0)        0 (0)      NS
    2                       20 (16.2)                                                      11 (8.9)                                                                                                                                  0 (0)      0 (0)              0 (0)        0 (0)      
    3                       7 (5.6)                                                        5 (4)                                                                                                                                     2 (8)      3 (12.0)           0 (0)        0 (0)      
    4                       2 (1.6)                                                        15 (12.1)                                                                                                                                 17 (80)    4 (16)             11 (73.4)    4          
  Duke stage                                                                                                                                                                                                                                                                               
    A                       39 (31.7)                                                      25 (20.3)                                              NS                                                                                 0 (0)      0 (0)      NS      0 (0)        0 (0)      NS
    B                       34 (27.6)                                                      8 (6.5)                                                                                                                                   5 (28)     2 (8)              0 (0)        0 (0)      
    C                       11 (8.9)                                                       5 (4)                                                                                                                                     12 (60)    3 (12.0)           1 (6.66)     0 (0)      
    D                       39 (31.7)                                                      13 (10.5)                                                                                                                                 1 (12)     2 (8)              10 (93.33)   3 (20.0)   
  Adenocarcinoma type                                                                                                                                                                                                                                                                      
    Partim mucnous          55 (44.7)                                                      48 (39.1)                                                                                                                                 6 (21.4)   2 (8)      NS      2 (13.3)     0 (0)      NS
    Nonmucinous             17 (13.8)                                                      3 (2.4)                                                NS                                                                                 12 (48)    5 (22.6)           9 (60.1)     4 (26.6)   
  Grade of malignancies                                                                                                                                                                                                                                                                    
    2                       68 (53.8)                                                      49 (39.8)                                              NS                                                                                 16 (64)    7 (28)     NS      11 (73.4)    4 (26.6)   NS
    3                       4 (4.8)                                                        2 (1.6)                                                                                                                                   2 (8)      0 (0)              0 (0)        0          
  Preoperative treatment                                                                                                                                                                                                                                                                   
    Yes                     14 (11.3)                                                      12 (9.7)                                               NS                                                                                 2 (8)      1 (6.6)    NS      0 (0)        0 (0)      0.037
    No                      67 (57.8)                                                      30 (21.2)                                                                                                                                 16 (64)    6 (21.4)           11 (73.4)    4 (26.6)   
  Postoperative treatment                                                                                                                                                                                                                                                                  
    Yes                     21 (19.5)                                                      15 (12.1)                                              NS                                                                                 8 (48)     4 (16)     0.018   4 (26.6)     2 (13.3)   NS
    No                      51 (41.6)                                                      3 6 (29.2)                                                                                                                                10 (52)    3 (12.0)           7 (46.8)     2 (13.3)   

NS, not statistically significant; TILs, tumor infiltrating lymphocytes.

###### 

Correlation between TILs in invasive primary tumor front, tumor cell deposits, and distant metastasis to liver and parameters of disease progression in patients with colorectal cancer.

                                                                TILs associated with the invasive front of primary tumor (N=123)   TILs associated with the deposits of cancer cells (N=25)   TILs associated with the invasive front of distant metastasis to liver (N=15)                                                           
  ------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------- ------------ ----------- ------- ----------- ---------- -------
  pT stage                                                                                                                                                                                                                                                                                                                            
    1                                                           2 (1.6)                                                            1 (0.8)                                                    NS                                                                              0 (0)        0 (0)       NS      0 (0)       0 (0)      0.004
    2                                                           31 (25.2)                                                          23 (18.6)                                                                                                                                  6 (24)       3 (12.0)            1 (6.6)     0 (0)      
    3                                                           38 (31.1)                                                          27 (21.9)                                                                                                                                  12 (45,4)    3 (12.0)            9 (60)      3 (20.0)   
    4                                                           1 (0.8)                                                            0 (0)                                                                                                                                      1 (6.6)      0 (0)               1 (6.6)     1 (6.6)    
  Venous invasion                                                                                                                                                                                                                                                                                                                     
    Absent                                                      51 (41.6)                                                          39 (31.7)                                                  0.012                                                                           10 (40)      4 (16)      NS      4 (60)      2 (13.3)   NS
    Present                                                     21 (17)                                                            12 (9.7)                                                                                                                                   8 (32)       3 (12.0)            7 (40)      2 (13.3)   
  Lymphatic invasion                                                                                                                                                                                                                                                                                                                  
    Absent                                                      58 (60.3)                                                          39 (31.7)                                                  0.009                                                                           13 (38)      2 (8)       NS      6 (66.6)    4 (26.6)   NS
    Present                                                     26 (21.2)                                                          12 (9.7)                                                                                                                                   5 (22)       5 (22)              5 (33.6)      0 (0)    
  Perineural invasion                                                                                                                                                                                                                                                                                                                 
    Absent                                                      65 (52.9)                                                          48 (39.1)                                                  0.017                                                                           15 (57.4)    6 (24)      NS      10 (93.3)   4 (26.6)   NS
    Present                                                     7 (5.6)                                                            3 (2.4)                                                                                                                                    3 (12.0)       1 (6.6)           1 (6.6)     0 (0)      
  Number of removed lymph nodes                                                                                                                                                                                                                                                                                                       
    \<5                                                         8 (6.5)                                                            2 (1.6)                                                    NS                                                                              2 (8)        1 (6.6)     NS      1 (6.6)     0 (0)      NS
    5--10                                                       13 (10.5)                                                          12 (9.7)                                                                                                                                   2 (8)        1 (6.6)             2 (13.3)    0 (0)      
    \>10                                                          51 (41.6)                                                        37 (30.1)                                                                                                                                  14 (48.8)    5 (22)              8 (53.4)    4 (26.6)   
  Lymph node metastasis                                                                                                                                                                                                                                                                                                               
    Absent                                                      42 (38.2)                                                          34 (27.6)                                                  0.022                                                                           7 (28)       3 (12.0)    NS      6 (40)      2 (13.3)   0.006
    Present                                                     30 (21.2)                                                          16 (13)                                                                                                                                      11 (44)    4 (16)              5 (33.4)    2 (13.3)   
  Number of metastatic lymph nodes                                                                                                                                                                                                                                                                                                    
    \<5                                                         28 (85.4)                                                          8 (6.5)                                                    0.007                                                                           8 (53.3)     2 (13.3)    NS      3 (20.0)    1 (6.6)    NS
    \>5                                                         8 (6.5)                                                            2 (1.6)                                                                                                                                      4 (20.1)   2 (13.3)            2 (13.3)    1 (6.6)    
  Lymph node pouch invasion                                                                                                                                                                                                                                                                                                           
    Absent                                                      10 (8.3)                                                           2(1.6)                                                     NS                                                                              2 (13.3)     1 (6.6)     NS      7 (66.7)    3 (20.0)   NS
    Present                                                       30 (21.2)                                                        4 (4.8)                                                                                                                                    6 (40)       6 (40)              4 (26.6)    1 (6.6)    
  Distant metastasis                                                                                                                                                                                                                                                                                                                  
    Absent                                                      --                                                                 --                                                         --                                                                              15 (62)      5 (22)      NS      0 (0)       0 (0)      NS
    Present                                                                                                                                                                                                                                                                   2 (8)        2 (8)               11 (100)    4 (26.6)   
  Distant metastasis size (mm)                                                                                                                                                                                                                                                                                                        
    \<10                                                        --                                                                 --                                                         --                                                                              2 (8)        0 (0)       NS      9 (60)      3 (20.0)   NS
    \>10                                                                                                                                                                                                                                                                      2 (8)        0 (0)               3 (26.7)    1 (6.6)    
  Tumor deposits                                                                                                                                                                                                                                                                                                                      
    Absent                                                      --                                                                 --                                                         --                                                                              0 (0)        0 (0)       NS      9 (60)      2 (13.3)   0.052
    Present                                                                                                                                                                                                                                                                   18 (72)      7 (28)              2 (13.3)    2 (13.3)   
  Inflammatory cell infiltrate in the invasive front of tumor                                                                                                                                                                                                                                                                         
    Absent                                                      8 (6.5)                                                            7 (5.6)                                                    0.002                                                                           2 (8)        1 (6.6)     0.042   2 (13.3)    1 (6.6)    NS
    Weak                                                          31 (25.2)                                                        23 (18.6)                                                                                                                                  6 (24)       4 (16)              3 (20.0)    2 (13.3)   
    Moderate                                                    17 (14.2)                                                            15 (12.1)                                                                                                                                7 (28)       2 (8)               5 (33.6)    1 (6.6)    
    Strong                                                      16 (13)                                                            6 (4.8)                                                                                                                                    3 (12.0)     0 (0)               1 (6.6)     0 (0)      
  Inflammatory cell infiltrate in the center of tumor mass                                                                                                                                                                                                                                                                            
    Absent                                                      6 (4.8)                                                            3 (2.4)                                                    0.003                                                                           1 (6.6)      0 (0)       NS      1 (6.6)     0 (0)      NS
    Weak                                                        21 (19.5)                                                          33 (24.5)                                                                                                                                  11 (34.2)    5 (22)              9 (60)      3 (20.0)   
    Moderate                                                    32 (26)                                                            12 (9.7)                                                                                                                                   3 (12.0)     1 (6.6)             0 (0)       1 (6.6)    
    Strong                                                      10 (8.3)                                                           6 (4.8)                                                                                                                                    3 (12.0)     1 (6.6)             1 (6.6)     0 (0)      

NS, not statistically significant; TILs, tumor infiltrating lymphocytes.
